These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 32109988)
1. Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression. Xia B; Wang J Drug Des Devel Ther; 2019; 13():3837-3844. PubMed ID: 32109988 [TBL] [Abstract][Full Text] [Related]
2. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459 [TBL] [Abstract][Full Text] [Related]
3. RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway. Niu H; Wu B; Peng Y; Jiang H; Zhang Y; Wang J; Zhang Y; He P Tumour Biol; 2015 Jan; 36(1):409-19. PubMed ID: 25266803 [TBL] [Abstract][Full Text] [Related]
4. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326 [TBL] [Abstract][Full Text] [Related]
5. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer. Ghosh S; Maity P J Environ Pathol Toxicol Oncol; 2010; 29(1):17-30. PubMed ID: 20528744 [TBL] [Abstract][Full Text] [Related]
6. RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer. Koh SA; Kim MK; Lee KH; Kim SW; Kim JR Clin Exp Metastasis; 2014 Oct; 31(7):805-15. PubMed ID: 25253431 [TBL] [Abstract][Full Text] [Related]
7. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627 [TBL] [Abstract][Full Text] [Related]
8. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma. Fang Y; Yi J; Lizhi L; Qiucheng C DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836 [TBL] [Abstract][Full Text] [Related]
9. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. Zhang M; Ding G; Zhou L; Shen T; Xu X; Zhao T; Jia S; Cao L J Interferon Cytokine Res; 2018 Sep; 38(9):413-422. PubMed ID: 30192158 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of RhoGDI2 mediated lung cancer epithelial-mesenchymal transition suppression. Niu H; Wu B; Jiang H; Li H; Zhang Y; Peng Y; He P Cell Physiol Biochem; 2014; 34(6):2007-16. PubMed ID: 25562149 [TBL] [Abstract][Full Text] [Related]
11. Pleuromutilin Inhibits Proliferation and Migration of A2780 and Caov-3 Ovarian Carcinoma Cells and Growth of Mouse A2780 Tumor Xenografts by Down-Regulation of pFAK2. Zhang B; Ma X; Li Y; Li S; Cheng J Med Sci Monit; 2020 Feb; 26():e920407. PubMed ID: 32041931 [TBL] [Abstract][Full Text] [Related]
12. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Ma JJ; Chen BL; Xin XY Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744 [TBL] [Abstract][Full Text] [Related]
13. RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells. Cho HJ; Park SM; Kim IK; Nam IK; Baek KE; Im MJ; Yoo JM; Park SH; Ryu KJ; Han HT; Kim HJ; Hong SC; Kim KD; Pak Y; Kim JW; Lee CW; Yoo J Oncotarget; 2014 Mar; 5(6):1554-64. PubMed ID: 24721928 [TBL] [Abstract][Full Text] [Related]
14. Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway. Xu M; Zhang Y Anticancer Agents Med Chem; 2019; 19(18):2243-2250. PubMed ID: 31660844 [TBL] [Abstract][Full Text] [Related]
15. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139 [TBL] [Abstract][Full Text] [Related]
16. RhoGDI stability is regulated by SUMOylation and ubiquitination via the AT1 receptor and participates in Ang II-induced smooth muscle proliferation and vascular remodeling. Dai F; Qi Y; Guan W; Meng G; Liu Z; Zhang T; Yao W Atherosclerosis; 2019 Sep; 288():124-136. PubMed ID: 31362179 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells. Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456 [TBL] [Abstract][Full Text] [Related]
18. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer. Wu B; Hu K; Li S; Zhu J; Gu L; Shen H; Hambly BD; Bao S; Di W Oncol Rep; 2012 Jan; 27(1):101-8. PubMed ID: 22025319 [TBL] [Abstract][Full Text] [Related]
19. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer]. Tang XH; Lu MS; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574 [No Abstract] [Full Text] [Related]
20. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer]. Tang X; Lu M; Li C; Deng S; Li M Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]